FDA Approves Label Expansion for generalized myasthenia gravis FDA expands approval of VYVGART and VYVGART Hytrulo to all ...

Generalised myasthenia gravis is a rare, long‑term autoimmune condition. It causes muscle weakness and extreme tiredness, and can affect breathing, speech, swallowing, eyesight and movement. Symptoms ...

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in ...

Label expansion enables serotype-agnostic use of FcRn blockade in adult gMG, positioning both IV Vyvgart and SC Vyvgart Hytrulo as first approved options regardless of antibody status. ADAPT SERON ...

The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization solely dedicated to the myasthenia gravis (MG) community, today launched the MGFA Food Support ...

The label expansion will include adults with AChR-Ab-negative gMG, making efgartigimod the first and only approved treatment for all serotypes of the rare neuromuscular disease.

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving ...

Argenx SE said the Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo, the company's treatments for a rare, chronic autoimmune disorder known as generalized ...

In a double-blind, placebo-controlled phase 2 randomized clinical trial, vemircopan did not meet the predefined efficacy ...

What is MG: An autoimmune neuromuscular disorder where antibodies disrupt nerve-to-muscle communication, causing fluctuating weakness in muscles used for vision, speech, swallowing, movement, and ...

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and ...